We study the basic physiological processes associated with cardiovascular diseases and create images to faithfully reflect these, allowing us to address major neurological and cardiovascular disorders.
By using imaging techniques to better understanding cardiac disease, we hope to improve the accuracy and ease of diagnosis and use this knowledge to improve patient care. As Cardiac Imaging Group Leader, Professor Stuart Grieve says: “we’re aiming to make very sensitive and specific tests that can help with clinical decision making.”
Several cardiac conditions are of interest to the group, including the looming epidemic of diabetes-related diastolic heart failure.
Generally, heart failure is only clinically apparent once the disease process is advanced, leaving the clinician with limited treatment options. A major focus of the group is the development of 4-dimensional flow magnetic resonance imaging (4D-flow MRI), a unique form of MRI that measures the fluid dynamics within the heart and vessels in a quick and non-invasive way. Recent advances in technology have made 4D-flow more feasible with the science is on the cusp of great change. “This technology is set to revolutionise not just cardiac imaging, but the daily practice of cardiology. The information that will be possible is far superior to anything that is currently available,” says Professor Grieve.
This project involves developing new translational image-based methods for better diagnosis and prognostication of aortic pathology. The aim is to provide new insights and update current approaches to aortic aneurysm; to generate clinically-practical approaches that influence current practice and improve healthcare outcomes for patients with aortic disease; and to generate and implement commercially viable models for these approaches.
This project involves the development of novel translational image-based methods for diagnosis and prognostication of heart failure. Using an exciting new approach based on CFD analysis of 4D flow and cardiac dynamic MRI data, we hope to provide new insights to update the current approaches in the diagnosis and treatment of heart failure and generate clinically practical approaches. This has the potential to inform changes in current clinical practice and to therefore improve healthcare outcomes for patients with aortic heart failure.
Originally from Christchurch, New Zealand, Bob Lee has experienced the research environment on both sides of the Tasman Sea. But while his life is currently in Sydney, Australia where the HRI is based, the ties to home remain strong for Bob.